NAD+
Investigación publicada y base de evidencia
Nicotinamide adenine dinucleotide (NAD+) is a redox cofactor and enzyme substrate for sirtuins, PARPs and CD38, and tissue NAD+ concentrations decline with age in preclinical models. Because NAD+ itself is poorly absorbed orally, most human work has used precursors, principally nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN); randomised trials consistently show these raise circulating NAD+ two- to threefold and are well tolerated over weeks to months. Functional and clinical endpoints are far less consistent: individual trials have reported improvements in walking distance, insulin sensitivity and sleep quality, while meta-analyses of muscle, glucose and lipid outcomes have been null. Lifespan extension and stem-cell rejuvenation findings are from rodent studies and have not been demonstrated in humans.
- NAD+ es un cofactor para sirtuinas, PARP y CD38 que disminuye con la edad en animales.
- Estudios humanos muestran que NR y NMN elevan NAD+ sanguíneo con resultados funcionales mixtos.
- Beneficios en longevidad y células madre provienen de estudios en roedores, no confirmados en humanos.
37 estudios · 22 desde 2023 · más reciente 2026
- Estudios citados
- 37
- Publicados en 2023+
- 22
- Artículo más reciente
- 2026
- Última revisión
- oct 2026
Temas recurrentes en la literatura
- Age-associated decline in tissue NAD+ and sirtuin/PARP/CD38 substrate availability
- Oral NAD+ precursor pharmacokinetics: NR and NMN reliably raise blood NAD+, NAD+ itself is not orally bioavailable
- Mitochondrial respiration, oxidative stress and skeletal-muscle function
- Dissociation between NAD+ elevation and clinical endpoint improvement
- Neurodegeneration and cerebral NAD+ (Parkinson's disease, mild cognitive impairment)
- Immunometabolism and the CD38-NAD+ axis
- Safety and tolerability across doses from 250 mg to 3000 mg per day
Identificadores del compuesto
- CAS
- 53-84-9
- PubChem
- 5892
Qué es NAD+, químicamente.
- Fórmula molecular
- C21H27N7O14P2
- Peso molecular
- 663.4 g/mol
- Número CAS
- 53-84-9
- PubChem CID
- 5892
nadide, coenzyme I, beta-NAD
Estas cifras provienen del registro PubChem para este compuesto y describen la base libre. El péptido liofilizado normalmente se suministra como sal de acetato o trifluoroacetato y contiene agua residual, por lo que la masa de polvo en un vial no es la misma cantidad que sugeriría el peso molecular anterior. La pureza cromatográfica en un certificado de análisis tampoco resuelve esa diferencia — cómo leer un certificado de análisis explica por qué.
37 estudios publicados.
Ordenados por solidez del diseño del estudio, luego por antigüedad. Cada entrada enlaza a su registro fuente para que el hallazgo pueda verificarse contra el artículo en lugar de tomarse bajo nuestra palabra.
- 01Revisión sistemática2026
Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis
Yang W, et al. · Nutrients · systematic review and random-effects meta-analysis of 15 parallel randomised controlled trials of oral NMN, doses 250-2000 mg/day, durations 14 days to 24 weeks, GRADE assessment
NMN did not increase overall, serious or system-specific adverse events and did not elevate ALT or AST. No significant effects were found on body weight, BMI, fasting glucose, HbA1c, lipids or systolic blood pressure; diastolic blood pressure decreased slightly and HOMA-IR showed a non-significant downward trend.
- 02Revisión sistemática2026
Domain-specific effects of NAD+ precursors on fatigue and functional performance: a systematic review and network meta-analysis.
Gao Y, et al. · Front Nutr · systematic review and network meta-analysis of 27 studies (25 RCTs), n=1,599 adults
No NAD+ precursor significantly improved perceived fatigue or sleep quality. NMN was associated with dose-dependent improvement in endurance outcomes without change in neuromuscular strength, NADH with the largest improvement in cognitive performance (sensitive to influential studies), and NMN with moderate quality-of-life improvement.
- 03Revisión sistemática2025
The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis
Prokopidis K, et al. · Journal of Cachexia, Sarcopenia and Muscle · systematic review and random-effects meta-analysis of randomised controlled trials of NMN or NR versus placebo, participant mean ages 60.9 to 83 years
NMN showed no significant effect on skeletal muscle index, handgrip strength, gait speed or the five-time chair stand test. NR was associated with longer 6-minute walk distance in peripheral artery disease but with poorer SPPB and chair-stand scores in mild cognitive impairment; the authors concluded current evidence does not support these precursors for preserving muscle mass or function.
- 04Clínico humano2026
The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans
Christen S, et al. · Nature Metabolism · randomised open-label placebo-controlled study, 65 healthy participants, 14 days of nicotinamide, nicotinamide riboside or nicotinamide mononucleotide, with ex vivo human microbiota fermentation and whole-blood assays
Nicotinamide riboside and nicotinamide mononucleotide comparably increased circulatory NAD+ over 14 days whereas nicotinamide did not, and only nicotinamide acutely altered the whole-blood NAD+ metabolome. Ex vivo work indicated NR and NMN are converted by gut microbiota to nicotinic acid, which was the potent direct NAD+ booster in whole blood.
- 05Clínico humano2026
Safety and efficacy of individualised exercise and NAD+ precursor supplementation in patients with Friedreich's ataxia in the USA: a single-centre, 2 × 2 factorial, randomised controlled trial
Lin KY, et al. · The Lancet Neurology · phase 2 single-centre 2 × 2 factorial randomised controlled trial, 66 individuals aged 10-40 with Friedreich's ataxia, 12 weeks of weight-based nicotinamide riboside (300-900 mg) and/or individualised home exercise
Nicotinamide riboside combined with exercise significantly increased peak VO2 versus control (difference 0.21 L/min, adjusted p = 0.0299), while nicotinamide riboside alone and exercise alone did not reach significance. Combination therapy was not statistically different from exercise alone, and all adverse events were mild or moderate.
- 06Clínico humano2026
A phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment
Martens CR, et al. · Alzheimer's & Dementia · 12-week phase II double-blind randomised placebo-controlled pilot trial, 42 older adults with amnestic mild cognitive impairment (NR n = 22, placebo n = 20)
Blood NAD+ approximately doubled in the NR group with no serious adverse effects, but the primary cognitive outcome, total cerebral blood flow and blood pressure were unchanged. Exploratory analysis suggested possible regional cerebral blood flow increases, particularly in the hippocampus.
- 07Clínico humano2026
Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial
Li H, et al. · Nature Medicine · single-arm open-label phase 1/2 trial, 25 adults with steroid-refractory or steroid-dependent immune thrombocytopenia, 450 mg NMN twice daily for 2 weeks, with supporting mouse macrophage experiments
NMN was well tolerated with no dose-limiting toxicities or treatment-related serious adverse events, and 5 of 25 patients (20.0%) met the primary platelet-response endpoint. The mechanistic work identified CD38-mediated NAD+ depletion driving M1-like macrophage polarisation and FcγRI-dependent platelet phagocytosis in mice.
- 08Clínico humano2026
Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting.
Reyna K, et al. · Front Aging · retrospective review of commercial-setting records, four consecutive days of IV NAD+ or IV NR with 30-day follow-up
Participants receiving IV NAD+ reported moderate to severe gastrointestinal symptoms, increased heart rate and chest pressure during infusions, which lengthened infusion time (mean 97 vs 37 minutes for IV NR); IV NR produced minor tingling and mild cramping. All symptoms resolved after infusion, and liver, kidney, thyroid and hsCRP markers did not change.
Hallazgo de seguridad reportado. Intravenous NAD+ infusions were associated with moderate to severe gastrointestinal symptoms, increased heart rate and chest pressure during administration that resolved on completion.
- 09Clínico humano2026
Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial.
Yu X, et al. · Am J Cardiovasc Drugs · single-centre randomised placebo-controlled trial, n=180 adults with heart failure due to ischaemic cardiomyopathy (LVEF ≤ 45%, NYHA II-III), 7 days of intravenous NAD+ added to guideline-directed therapy, 6-month follow-up
At 1 month, LVEF was higher in the NAD+ group than with placebo (45.44% vs 42.44%, p = 0.024). NT-proBNP at day 7, the 6-month composite of major cardiac and cerebrovascular events (14.6% vs 24.7%, p = 0.089) and NYHA class improvement showed non-significant trends favouring NAD+, and left ventricular structural measures did not differ.
- 10Clínico humano2026
Oral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial.
Kornilov SA, et al. · Geroscience · double-blind randomised placebo-controlled phase 0/1b trial (RENEWAL-NAD+), 60 healthy adults aged 45-75 randomised (n = 50 in the primary analysis), 5 days of oral LathMized NAD+
Oral LNAD+ raised whole-blood intracellular NAD by 53% versus placebo at day 6, while plasma NAD was unchanged (p = 0.60) and plasma NAD catabolites rose. Symptom incidence was similar between groups, with one mild nausea event in the LNAD+ arm, and no secondary clinical, vital-sign, wellbeing or wearable endpoint survived multiplicity correction.
- 11Clínico humano2026
NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial.
Gao M, et al. · Laryngoscope · randomised double-blind controlled trial, n=38 adults with sudden sensorineural hearing loss, NAD+ plus standard treatment versus standard treatment alone, 3-month follow-up
Hearing improved more with NAD+ (40.21 vs 23.06 dB HL, p = 0.010), the effective rate was higher (94.44% vs 60.00%) and mean recovery time was shorter (62.97 vs 175.98 days, p = 0.028); tinnitus and aural fullness also improved more. The abstract does not state the route of NAD+ administration.
- 12Clínico humano2026
Efficacy and Safety of a Topical Nicotinamide Adenine Dinucleotide Skinbooster for the Treatment of Melasma.
Yi KH, et al. · Aesthetic Plast Surg · prospective single-centre case series, 36 Korean women with mixed-type melasma, microneedling immediately followed by topical sterile NAD+ over 21 weeks
Mean MASI fell from 16.8 to 6.9 at week 21 (59.2% improvement, p < 0.001), and blinded assessment rated 83.3% of patients as improved; only transient erythema and oedema were reported. There was no control group, so the effect of NAD+ cannot be separated from microneedling.
- 13Clínico humano2025
Nicotinamide riboside combined with exercise to treat hypertension in middle-aged and older adults: a pilot randomized clinical trial
Lin Y, et al. · GeroScience · double-blind pilot randomised trial, 54 sedentary adults aged 55+ with daytime systolic BP at or above 130 mmHg, 6 weeks of 1000 mg/day NR plus supervised walking, placebo plus walking, or NR alone
NR plus exercise was not superior to placebo plus exercise for the primary outcome of daytime systolic blood pressure. NAD+ catabolites were higher in the NR groups, and post hoc analysis showed a trend toward greater nighttime blood pressure reduction in unmedicated participants.
- 14Clínico humano2025
Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial
Wu CY, et al. · EClinicalMedicine · 24-week double-blind placebo-controlled trial with placebo lead-in, 58 adults with long-COVID, 2000 mg/day nicotinamide riboside
NR raised blood NAD+ 2.6- to 3.1-fold within 5 to 10 weeks and elevation persisted to 20 weeks. There were no significant between-group differences in cognition, fatigue, sleep quality, anxiety or depression, and dropout was substantially higher in the NR arm.
- 15Clínico humano2024
Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial
McDermott MM, et al. · Nature Communications · randomised double-blind placebo-controlled trial, 90 adults with lower-extremity peripheral artery disease, 6 months of nicotinamide riboside with or without resveratrol
Nicotinamide riboside improved 6-minute walk distance compared with placebo (between-group difference +17.6 m), with a larger difference of 31.0 m among participants taking at least 75% of study pills. Adding resveratrol conferred no additional benefit.
- 16Clínico humano2024
Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study
Morifuji M, et al. · GeroScience · randomised double-blind placebo-controlled parallel-group trial, 60 older adults, 250 mg/day NMN for 12 weeks
The primary outcome, a stepping test, showed no significant difference between groups at 4 or 12 weeks. Secondary outcomes favoured NMN: blood NAD+ and its metabolites rose, 4-metre walking time was shorter and Pittsburgh Sleep Quality Index scores improved versus placebo.
- 17Clínico humano2024
Effects of Nicotinamide Adenine Dinucleotide on Older Patients with Heart Failure.
Pei Z, et al. · Rev Cardiovasc Med · randomised saline-controlled trial, n=60 older adults with heart failure on conventional therapy, 7 days of NAD+ injections in saline
Improvements in NT-proBNP and LVEF were numerically greater with NAD+ than with saline but not statistically significant. The authors reported more favourable serum sirtuin (SIRT1, SIRT3, SIRT6), reactive oxygen species and endothelin levels in the NAD+ group; the trial was registered retrospectively.
- 18Clínico humano2024
Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19.
Isman A, et al. · Brain Behav Immun Health · single-arm pilot study, 36 patients with moderate or severe fatigue persisting after COVID-19, 12 weeks of low-dose naltrexone plus NAD+ delivered by iontophoresis patches
SF-36 total score rose from 36.5 to 52.1 and Chalder fatigue score fell from 25.9 to 17.4 after 12 weeks (both p < 0.0001), with 52% classed as responders. Iontophoresis patches caused mild, short-lived skin irritation in 25% of patients. Without a control group and with naltrexone given alongside, the contribution of NAD+ cannot be separated.
- 19Clínico humano2023
The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
Yi L, et al. · GeroScience · randomised multicentre double-blind placebo-controlled parallel-group trial, 80 healthy middle-aged adults, placebo or 300/600/900 mg/day NMN for 60 days
All NMN doses significantly raised blood NAD+ versus placebo and were well tolerated with no safety signals. Six-minute walk distance and SF-36 scores improved versus placebo, with the largest effects at 600 mg/day; HOMA-IR did not differ significantly.
- 20Clínico humano2023
NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease.
Berven H, et al. · Nat Commun · phase 1 randomised double-blind placebo-controlled trial, n=20 with Parkinson's disease, 4 weeks of high-dose NR
High-dose nicotinamide riboside produced no moderate or severe adverse events and no excess of mild adverse events versus placebo, and raised whole-blood NAD+ up to about five-fold; a slight early rise in serum homocysteine was observed without depletion of the methyl donor pool.
Hallazgo de seguridad reportado. A slight initial rise in serum homocysteine was observed with high-dose nicotinamide riboside, with the methyl donor pool remaining intact.
- 21Clínico humano2022
Nicotinamide Adenine Dinucleotide (NAD+) and Enkephalinase Inhibition (IV1114589NAD) Infusions Significantly Attenuate Psychiatric Burden Sequalae in Substance Use Disorder (SUD) in Fifty Cases.
Blum K, et al. · Curr Psychiatry Res Rev · uncontrolled case series of fifty treatment-resistant poly-drug users with substance use disorder given intravenous NAD+ with enkephalinase-inhibition infusions (IV1114589NAD)
Self-rated craving, anxiety and depression scores fell from baseline after the infusions (craving P=1.063E-9), following a dose-dependent linear trend, and urine drug tests in a subset of 40 patients midway through were negative. There was no control group, outcomes were Likert self-ratings, and the infusions contained ingredients besides NAD+.
- 22Clínico humano2021
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Yoshino M, et al. · Science · randomised double-blind placebo-controlled trial, 25 postmenopausal women with prediabetes and overweight/obesity, 250 mg/day NMN for 10 weeks, hyperinsulinaemic-euglycaemic clamp
NMN increased muscle insulin sensitivity and insulin-signalling gene expression relative to placebo. Body composition, hepatic and whole-body insulin sensitivity, blood pressure and lipids were not significantly changed.
- 23Clínico humano2021
Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study.
Liao B, et al. · J Int Soc Sports Nutr · randomised double-blind placebo-controlled four-arm trial, n=48 recreational runners, 6 weeks with training
Compared with placebo, the two higher-dose NMN groups showed greater increases in oxygen uptake and power at the first and second ventilatory thresholds; VO2max, O2-pulse and peak power did not change from baseline in any group.
- 24Clínico humano2019
A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD.
Grant R, et al. · Front Aging Neurosci · open pilot pharmacokinetic study of a 6-hour intravenous NAD+ infusion in healthy adults
During a 6-hour intravenous infusion, plasma NAD+ and its metabolites did not rise for the first 2 hours, indicating rapid and complete removal of infused NAD+ from plasma; the metabolite profile was consistent with NAD+ glycohydrolase and pyrophosphatase activity, and urinary NAD+ and methylnicotinamide increased by 6 hours.
- 25Clínico humano2018
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults.
Martens CR, et al. · Nat Commun · randomised double-blind placebo-controlled crossover trial, 2 x 6 weeks, healthy middle-aged and older adults
Chronic nicotinamide riboside was well tolerated and increased NAD+ metabolism in healthy middle-aged and older adults; exploratory physiological outcomes suggested possible effects on blood pressure and arterial stiffness that the authors flagged for further trials.
- 26Clínico humano2018
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
Dollerup OL, et al. · Am J Clin Nutr · randomised double-blind placebo-controlled parallel trial, n=40 obese insulin-resistant men, 12 weeks
Twelve weeks of nicotinamide riboside did not improve clamp-measured insulin sensitivity, endogenous glucose production, glucose disposal, resting energy expenditure, lipolysis, lipid oxidation or body composition; no serious adverse events occurred and safety blood tests were normal.
- 27Clínico humano2016
Nicotinamide riboside is uniquely and orally bioavailable in mice and humans
Trammell SA, et al. · Nature Communications · quantitative NAD+ metabolomics in mice plus first-in-human single oral doses of nicotinamide riboside in healthy adults
Oral nicotinamide riboside raised blood NAD+ in humans in a dose-dependent manner and did so more effectively than equivalent molar doses of nicotinamide or nicotinic acid. The work established the analytical basis for measuring the NAD+ metabolome.
- 28Clínico humano2007
In search for new antipsoriatic agents: NAD topical composition.
Wozniacka A, et al. · Skin Pharmacol Physiol · within-patient controlled trial, n=37 patients with psoriasis, two matched plaques per patient, 4 weeks of topical NAD+ ointment compared with anthralin and placebo
After 4 weeks, reductions in erythema, infiltration and desquamation with topical NAD+ were similar to those with anthralin. NAD+ decomposed considerably in the ointment at room temperature but was stable when refrigerated.
- 29Clínico humano1971
Sleep, psychological and clinical changes during alcohol withdrawal in NAD-treated alcoholics.
Smith JW, et al. · Q J Stud Alcohol · controlled clinical trial in people with alcoholism during withdrawal; design details and numbers are not in the registry record (no abstract)
The PubMed record has no abstract; the title describes sleep, psychological and clinical changes during alcohol withdrawal in NAD-treated alcoholics. Results are not available in the abstract.
- 30Clínico humano1969
The behavioral effects of nicotinamide adenine dinucleotide in chronic schizophrenia.
Meltzer H, et al. · Psychopharmacologia · controlled clinical trial of behavioural effects in patients with chronic schizophrenia; design details and numbers are not in the registry record (no abstract)
The PubMed record has no abstract; the title describes the behavioural effects of nicotinamide adenine dinucleotide in chronic schizophrenia. Results are not available in the abstract.
- 31Clínico humano1969
NAD effects on the biochemistry and psychological performance of alcoholics under ethanol stress.
Rappaport M · Q J Stud Alcohol · controlled clinical trial in people with alcoholism under an ethanol challenge; design details and numbers are not in the registry record (no abstract)
The PubMed record has no abstract; the title describes the effects of NAD on biochemistry and psychological performance in alcoholics under ethanol stress. Results are not available in the abstract.
- 32Clínico humano1968
Nicotinamide adenine dinucleotide in the treatment of chronic schizophrenic patients.
Hoffer A, Osmond H · Br J Psychiatry · controlled clinical trial in patients with chronic schizophrenia; design details and numbers are not in the registry record (no abstract)
The PubMed record has no abstract; the title describes nicotinamide adenine dinucleotide used to treat chronic schizophrenic patients. Results are not available in the abstract.
- 33Clínico humano1967
Controlled evaluation of nicotinamide adenine dinucleotide in the treatment of chronic schizophrenic patients.
Kline NS, et al. · Br J Psychiatry · controlled clinical trial in patients with chronic schizophrenia; design details and numbers are not in the registry record (no abstract)
The PubMed record has no abstract; the title describes a controlled evaluation of nicotinamide adenine dinucleotide as treatment for chronic schizophrenia. Results are not available in the abstract.
- 34Animal in vivo2016
NAD⁺ repletion improves mitochondrial and stem cell function and enhances life span in mice
Zhang H, et al. · Science · aged mice supplemented with nicotinamide riboside; muscle, neural and melanocyte stem cell assays
Nicotinamide riboside supplementation restored mitochondrial function in muscle stem cells of aged mice and modestly extended murine lifespan. These outcomes were observed in mice only and have not been reproduced in humans.
- 35Revisión2021
NAD⁺ metabolism and its roles in cellular processes during ageing
Covarrubias AJ, et al. · Nature Reviews Molecular Cell Biology · narrative review of NAD+ biosynthesis, consumption and age-related decline
The review summarised evidence that NAD+ availability falls with age across tissues and that sirtuins, PARPs and CD38 compete for the same NAD+ pool. It framed NAD+ decline as a contributor to mitochondrial dysfunction and inflammation in ageing models.
- 36Reporte de caso2026
Symptomatic and Ultrasonographic Improvement in Rheumatoid Arthritis Temporally Associated with Intravenous NAD+ Therapy: A Case Report.
Itani MR, et al. · ACR Open Rheumatol · single case, 49-year-old woman with rheumatoid arthritis who received a short course of intravenous NAD+ infusions for aesthetic and anti-ageing purposes
She reported pain relief after infusions and later improvement in swelling, morning stiffness, function and analgesic use, and ultrasonography nine months later showed no synovitis; no infusion-related adverse events were reported. The authors stated that previous methotrexate, concurrent psychosocial changes and incomplete diagnostic documentation preclude causal inference.
- 37Reporte de caso2026
Rapid Wound Healing Observed Following Oral LathMized NAD+ Supplementation: A Case Study.
Hastings WJ, et al. · Plast Reconstr Surg Glob Open · single case, 59-year-old woman with surgical wound dehiscence after cosmetic body-contouring surgery who started oral LathMized NAD+ on her own initiative
The wound progressed from full-thickness dehiscence to complete closure without scar by day 22 of supplementation (postoperative day 40), and no adverse reactions were reported. A single uncontrolled case cannot show that the supplement caused the healing.
Lo que esta evidencia no establece.
Human trials reliably show that oral NR and NMN raise circulating NAD+ and are well tolerated for up to about six months, but no trial has demonstrated that this translates into durable improvements in muscle mass, cognition, glycaemic control or blood pressure, and meta-analyses of these endpoints are null. Lifespan extension, stem-cell rejuvenation and tissue NAD+ restoration remain rodent findings; no human data address long-term safety beyond six months, optimal dosing, or whether individuals with low baseline NAD+ respond differently.
Preguntas comunes sobre la investigación.
- What is NAD+?
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in all living cells. It carries electrons in central energy metabolism and acts as the consumed co-substrate for the sirtuin, PARP, and CD38 enzyme families studied in ageing and metabolic research.
- How does direct NAD+ differ from precursors such as NR or NMN?
Nicotinamide riboside and nicotinamide mononucleotide are precursors that enter the salvage pathway and are converted to NAD+ inside the cell, whereas NAD+ itself is the intact dinucleotide. The cited reviews discuss the bioavailability trade-offs between the two strategies, including evidence that circulating NAD+ is extensively metabolised before uptake.
- Why has most human research used NAD+ precursors rather than NAD+ itself?
NAD+ itself is poorly absorbed orally, so published human work has overwhelmingly used the precursors nicotinamide riboside and nicotinamide mononucleotide. Randomised trials consistently report that these raise circulating NAD+ two- to threefold and are well tolerated over weeks to months. Functional endpoints have been far less consistent: individual trials reported improvements in walking distance, insulin sensitivity and sleep quality, while meta-analyses of muscle, glucose and lipid outcomes were null.
Disponible en nuestro catálogo
Solo para fines de investigación. No apto para consumo humano, diagnóstico, tratamiento o prevención de ninguna condición. Nada en esta página constituye consejo médico, y ningún estudio resumido aquí debe leerse como una recomendación.